105 related articles for article (PubMed ID: 1153148)
1. Use of medroxyprogesterone acetate to prevent menopausal symptoms.
Bullock JL; Massey FM; Gambrell RD
Obstet Gynecol; 1975 Aug; 46(2):165-8. PubMed ID: 1153148
[TBL] [Abstract][Full Text] [Related]
2. Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women.
Lobo RA; McCormick W; Singer F; Roy S
Obstet Gynecol; 1984 Jan; 63(1):1-5. PubMed ID: 6318170
[TBL] [Abstract][Full Text] [Related]
3. [Conservative surgery combined with depot medroxyprogesterone acetate in treatment of moderate or severe endometriosis].
Zhou J; Lei ZW; Lü JQ; Sun J; Xu XW
Zhonghua Fu Chan Ke Za Zhi; 2005 Jan; 40(1):5-8. PubMed ID: 15774083
[TBL] [Abstract][Full Text] [Related]
4. Oral medroxyprogesterone in the treatment of postmenopausal symptoms.
Schiff I; Tulchinsky D; Cramer D; Ryan KJ
JAMA; 1980 Sep; 244(13):1443-5. PubMed ID: 6775094
[TBL] [Abstract][Full Text] [Related]
5. Depo-Provera in the treatment of recurrent vulvovaginal candidiasis.
Dennerstein GJ
J Reprod Med; 1986 Sep; 31(9):801-3. PubMed ID: 2945926
[TBL] [Abstract][Full Text] [Related]
6. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
Klaassen DJ; Rapp EF; Hirte WE
Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
[TBL] [Abstract][Full Text] [Related]
7. Efficacy comparison of Pueraria mirifica (PM) against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of climacteric symptoms in perimenopausal women: phase III study.
Chandeying V; Sangthawan M
J Med Assoc Thai; 2007 Sep; 90(9):1720-6. PubMed ID: 17957910
[TBL] [Abstract][Full Text] [Related]
8. The use of medroxyprogesterone acetate for relief of climacteric symptoms.
Morrison JC; Martin DC; Blair RA; Anderson GD; Kincheloe BW; Bates GW; Hendrix JW; Rivlin ME; Forman EK; Propst MG; Needham R
Am J Obstet Gynecol; 1980 Sep; 138(1):99-104. PubMed ID: 7416212
[TBL] [Abstract][Full Text] [Related]
9. [Therapy of the surgical menopause syndrome with depot medroxyprogesterone acetate and its objective evaluation testing the reaction of the anterior pituitary gland to stimulation with gonadotropin-releasing hormone].
Boschitsch E; Gitsch E; Spona J
Wien Klin Wochenschr; 1983 Oct; 95(20):718-24. PubMed ID: 6229096
[TBL] [Abstract][Full Text] [Related]
10. An investigation into the climacteric in Nigerians.
Aina AO
J Med Assoc Thai; 1992 Mar; 75(3):168-72. PubMed ID: 1506795
[TBL] [Abstract][Full Text] [Related]
11. Plasma levels of estrogen, luteinizing hormone, and follicle stimulating hormone following castration and estradiol implant.
Hunter DJ; Julier D; Franklin M; Green E
Obstet Gynecol; 1977 Feb; 49(2):180-5. PubMed ID: 834401
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a continuous estrogen-progestin regimen in the menopausal patient.
Weinstein L
Obstet Gynecol; 1987 Jun; 69(6):929-32. PubMed ID: 3574823
[TBL] [Abstract][Full Text] [Related]
13. Depo Provera. Position paper on clinical use, effectiveness and side effects.
Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
[TBL] [Abstract][Full Text] [Related]
14. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone.
Hargrove JT; Maxson WS; Wentz AC; Burnett LS
Obstet Gynecol; 1989 Apr; 73(4):606-12. PubMed ID: 2538787
[TBL] [Abstract][Full Text] [Related]
15. Use of depo-provera in teens.
Khoiny FE
J Pediatr Health Care; 1996; 10(5):195-201. PubMed ID: 8920351
[TBL] [Abstract][Full Text] [Related]
16. Double-blind, placebo-controlled, crossover trial of propranolol as treatment for menopausal vasomotor symptoms.
Alcoff JM; Campbell D; Tribble D; Oldfield B; Cruess D
Clin Ther; 1981; 3(5):356-64. PubMed ID: 7471131
[TBL] [Abstract][Full Text] [Related]
17. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist plus medroxyprogesterone acetate.
Cedars MI; Lu JK; Meldrum DR; Judd HL
Obstet Gynecol; 1990 Apr; 75(4):641-5. PubMed ID: 2138265
[TBL] [Abstract][Full Text] [Related]
18. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.
Beex L; Burghouts J; van Turnhout J; Breed W; Hillen H; Holdrinet A; Boetius G; Hoogendoorn G; Doesburg W; Verhulst M
Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524
[TBL] [Abstract][Full Text] [Related]
19. Effect of oral medroxyprogesterone acetate on menopausal symptoms in patients with endometrial carcinoma.
Aslaksen K; Frankendal B
Acta Obstet Gynecol Scand; 1982; 61(5):423-8. PubMed ID: 6760653
[TBL] [Abstract][Full Text] [Related]
20. Comparison of lipid and androgen levels after conjugated estrogen or depo-medroxyprogesterone acetate treatment in postmenopausal women.
Barnes RB; Roy S; Lobo RA
Obstet Gynecol; 1985 Aug; 66(2):216-9. PubMed ID: 2991832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
